CI - Cigna Corporation

NYSE - NYSE Delayed Price. Currency in USD
172.10
+1.49 (+0.87%)
At close: 4:02PM EDT

172.10 0.00 (0.00%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Previous Close170.61
Open170.48
Bid172.08 x 1100
Ask172.09 x 900
Day's Range168.66 - 172.68
52 Week Range141.95 - 226.61
Volume1,614,404
Avg. Volume2,267,493
Market Cap65.305B
Beta (3Y Monthly)0.99
PE Ratio (TTM)15.86
EPS (TTM)10.85
Earnings DateAug 1, 2019
Forward Dividend & Yield0.04 (0.02%)
Ex-Dividend Date2019-03-08
1y Target Est213.45
Trade prices are not sourced from all markets
  • Zacksyesterday

    Stocks Slip This Week on Earnings, Fed Uncertainties

    Stocks Slip This Week on Earnings, Fed Uncertainties

  • Surprise medical bills could soon be curbed by federal laws
    Yahoo Finance5 days ago

    Surprise medical bills could soon be curbed by federal laws

    The Energy and Commerce Committee in the U.S. House of Representatives advanced several health care initiatives Wednesday, the most significant of which could curb surprise medical bills.

  • Webster Financial Corp (Conn) (WBS) Q2 2018 Earnings Call Transcript
    Motley Fool5 days ago

    Webster Financial Corp (Conn) (WBS) Q2 2018 Earnings Call Transcript

    WBS earnings call for the period ending June 30, 2019.

  • New IRS rules gives high deductible plans richer care benefits
    Yahoo Finance6 days ago

    New IRS rules gives high deductible plans richer care benefits

    The Treasury Department and IRS issued a notice Wednesday that will help high deductible plan enrollees qualify for more preventative care benefits, which expands the uses for Health Savings Accounts.

  • Business Wire6 days ago

    Cigna and Express Scripts Named Best Places to Work for Disability Inclusion

    Global health service company Cigna and its Express Scripts business were both named as a Best Place to Work for Disability Inclusion after earning scores of 100 on the 2019 Disability Equality Index® (DEI). The index is a joint initiative of the American Association of People with Disabilities (AAPD) and Disability:IN, and measures inclusion across six categories: culture and leadership, enterprise-wide access, employment practices, community engagement, supplier diversity and non-U.S. operations. As part of the company’s commitment to diversity and inclusion, Cigna and Express Scripts have active employee groups, People With Different Abilities (PWDA) and ExpressPossAbilities (ExPA).

  • GuruFocus.com7 days ago

    Dodge & Cox Stock Fund 2nd-Quarter Commentary

    Discussion of markets and holdings Continue reading...

  • More St. Louis companies are buyers than sellers
    American City Business Journals7 days ago

    More St. Louis companies are buyers than sellers

    St. Louis companies continue to be buyers in the mergers and acquisitions market. Of 98 transactions in the first half of 2019, 61 were acquisitions by St. Louis companies, and 37 were sales by St. Louis companies, according to The Fortune Group, an M&A advisory firm. It’s a trend that goes back 10 years and is in contrast to the negative trend – and image – of large public companies headquartered in St. Louis relocating or selling to companies with headquarters elsewhere.

  • Health care 'Cadillac Tax' repeal bill up for vote Wednesday
    Yahoo Finance7 days ago

    Health care 'Cadillac Tax' repeal bill up for vote Wednesday

    Congress will be voting Wednesday on a repeal of what is known as the “Cadillac Tax”—a provision of the Affordable Care Act which would place a 40% tax on employer-sponsored health care plans which provide excess benefits.

  • How Express Scripts Makes Money: The Delivery of Prescription Drugs
    Investopedia8 days ago

    How Express Scripts Makes Money: The Delivery of Prescription Drugs

    The pharmacy benefit management company is now a wholly-owned subsidiary of Cigna, but it is a major earner: in 2017, Express Scripts brought in more than $100 billion in revenues.

  • Cigna is Rebounding: Should Investors Get on Board?
    TipRanks8 days ago

    Cigna is Rebounding: Should Investors Get on Board?

    Following the news on July 11 that the Trump administration dropped their proposal to eliminate rebates for drug manufacturers and pharmacy benefit managers (PBM), Cigna Corp (CI) surged 9%. The company’s profits would have taken a major hit had the ban gone into effect. While the stock is down 6% year-to-date, analysts believe a rebound is coming. With its August 1 earnings release date quickly approaching, we enlisted the help of TipRanks to find out if Cigna really is on the road to recovery. Cigna Relies on PBM SegmentCigna is a health insurance company based in Philadelphia, Pennsylvania offering a wide variety of medical, supplemental, dental and Medicare plans. The proposed rule would have prevented drug makers from giving discounts and rebates to insurers or PBMs for putting a particular drug on a list of drugs covered by health plans. PBMs were first used to help insurance companies manage prescription claims for patients with Medicare Part D plans. Now they are responsible for drug utilization review, formulary management, determining which pharmacies are in network as well as reimbursements given to pharmacies. Had the President been able to ban drug rebates, the effects would have been catastrophic for insurance providers. Cigna along with several others shifted focus towards making PBMs a key component of their business models. The company recently increased their exposure to the PBM sector after acquiring Express Scripts for $67 billion in December. The goal of the acquisition was to lower costs and improve the quality of treatments by providing access medical care and pharmacy benefits in one single place. Even with the decline caused by the threat of rebate cuts, sentiment regarding the company and its ability to make a comeback is positive. News Sentiment on CI A Strong Q1 The company had a strong first quarter, with total revenue reaching $38 billion up from $11 billion in Q1 2018. Shareholder net income grew to $1.4 billion from $0.9 billion over the same time period. EPS increased to $3.90 per share, surpassing the Street’s prediction of $3.73 per share. Cigna also exceeded the $33.1 billion estimate for adjusted revenue, with the actual result being $33.4 billion. Management attributed this growth to the Express Scripts acquisition as well as its health coverage plans for medium and large-sized companies. President and CEO, David Cordani said, “Cigna's first quarter performance reflects focused execution of our proven growth strategy and positions us well to achieve our increased outlook for 2019.” Going Forward Into Q2Ahead of the Q2 earnings release, management is confident more gains are on the way. The company updated its guidance on May 2, saying 2019 adjusted revenue should fall within the range of $133 billion to $135 billion. This is up from the original estimate of $132 billion to $134 billion. Five-star analyst, Steven Halper, believes that the acquisition wasn’t fully appreciated by investors. “We view the merger with ESRX favorably as the combined company could generate significant synergies and free cash flow. We continue to believe that CI’s risk/ reward tradeoff is highly compelling. $245 price target is supported by our DCF analysis,” he said on May 2 when explaining his decision to reiterate his Buy rating and $245 price target. Charles Rhyee, a Cowen & Co. analyst, believes that despite a decline in Q1 2019 Health Services adjusted operating profit amounting to 12% year-over-year, investors should not be concerned. “On the face of it, this decrease would suggest something is wrong, but we don't believe that's necessarily the case. We believe one factor driving this could be investment spending to realize cost synergies that are not broken out separately as one-time items,” he said. On May 7, the analyst reiterated his Buy rating on the stock despite lowering the price target from $264 to $254. The Bottom Line Wall Street is bullish on Cigna. The stock has a ‘Strong Buy’ analyst consensus, with 10 out of 10 analysts giving the stock a buy rating over the last three months. The average price target is $221, suggesting upside potential of 23%. Analyst Ratings & Price Targets on CI

  • MarketWatch10 days ago

    Health care is one of the stock market’s healthiest sectors right now

    DEEP DIVE Despite all the good economic news, earnings growth is expected to slow to a crawl this year for large U.S. companies. It may also surprise you that the health-care sector is seen as one of the exceptions.

  • Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback
    Zacks11 days ago

    Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback

    Cigna's (CI) Pharmacy Benefits management is poised to gain due to the pullback of the drug rebate proposal.

  • ETFs to Shine as Trump Tosses Drug Rebate Curb Plan
    Zacks11 days ago

    ETFs to Shine as Trump Tosses Drug Rebate Curb Plan

    We study the impact of Trump's dropping of the proposed drug rebate rule on some health ETFs with exposure to pharmacy benefit managers and healthcare insurers.

  • Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
    Zacks11 days ago

    Drug Pricing Woes Linger on Repealing Drug Rebate Proposal

    Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.

  • Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
    Yahoo Finance11 days ago

    Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump

    Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.

  • Company News for Jul 12, 2019
    Zacks11 days ago

    Company News for Jul 12, 2019

    Companies in the news are: CI, DAL, BBBY and FAST

  • Stock Market Hits Record High On Fed Chief Powell; Cisco Buys Acacia, Delta Earnings Top, Cigna Flies On Rebate Rule Reversal: Weekly Review
    Investor's Business Daily11 days ago

    Stock Market Hits Record High On Fed Chief Powell; Cisco Buys Acacia, Delta Earnings Top, Cigna Flies On Rebate Rule Reversal: Weekly Review

    The stock market hit highs this week as Fed chief Jerome Powell signaled a July 31 Fed rate cut. Cisco will buy Acacia, Delta earnings beat, Cigna soared on a drug rebate rule reversal.

  • Health Insurers Rejoice on Pullback of Drug Rebate Plan
    Zacks11 days ago

    Health Insurers Rejoice on Pullback of Drug Rebate Plan

    After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.

  • This Rebate Decision Saw Health Insurers Soar Yesterday
    Market Realist11 days ago

    This Rebate Decision Saw Health Insurers Soar Yesterday

    On Thursday, the Trump administration announced the withdrawal of the proposal to abolish rebates paid to pharmacy benefit managers by drugmakers.

  • Cigna (CI) Jumps: Stock Rises 9.2%
    Zacks11 days ago

    Cigna (CI) Jumps: Stock Rises 9.2%

    Cigna (CI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
    Zacks12 days ago

    Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play

    The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.

  • GuruFocus.com12 days ago

    Dow Jones Passes 27,000 for the 1st Time

    Bed Bath & Beyond slumps on quarterly results Continue reading...

  • Why Cigna, Weight Watchers International, and AAR Jumped Today
    Motley Fool12 days ago

    Why Cigna, Weight Watchers International, and AAR Jumped Today

    These stocks weathered a volatile session to produce big gains.

  • Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
    Yahoo Finance12 days ago

    Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates

    The drug companies provide rebates to PBMs in exchange for distributing their products.

  • Dow, S&P end in record territory after Powell boosts expectations for Fed rate cut
    MarketWatch12 days ago

    Dow, S&P end in record territory after Powell boosts expectations for Fed rate cut

    Nasdaq closed 6 points lower, even as Federal Reserve Chairman Jerome Powell reinforced expectations for an interest rate cut later this month.